Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.

about

GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes Investigating the effects of physiological bile acids on GLP-1 secretion and glucose tolerance in normal and GLP-1R(-/-) mice.

P2860

Q34718860-E9072862-2457-423F-862C-0FD6D7E37798 Q50522015-87829426-8F77-42C5-9E45-94F81E9A1C18

P2860

Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.

Item

http://www.wikidata.org/entity/Q38305288

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Metabolic effects of sub-chron ...... n obese diabetic (ob/ob) mice.

@en

type

Item

label

Metabolic effects of sub-chron ...... n obese diabetic (ob/ob) mice.

@en

prefLabel

Metabolic effects of sub-chron ...... n obese diabetic (ob/ob) mice.

@en

P1476

Metabolic effects of sub-chron ...... in obese diabetic (ob/ob) mice

@en

P2093

Brian D Green

http://www.w3.org/2001/XMLSchema#string

Kerry S Lavery

http://www.w3.org/2001/XMLSchema#string

P2860

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice

Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor

The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.

Gastric inhibitory polypeptide: the neglected incretin revisited.

Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.

Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.

Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide.

Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes.

Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.

P304

221-226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1515/BC.2007.024

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

388

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6543285

http://www.w3.org/2001/XMLSchema#string

P698

17261085

http://www.w3.org/2001/XMLSchema#string

P921

Adipositas

Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.

about

P2860

P2860

Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921